Related Experiment Video
Updated: Jul 10, 2026
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Polatuzumab Vedotin Enhances Intratumoral T-Cell Infiltration and Demonstrates Combinatorial Efficacy With
Mayu Tomita1, Sei Shu1, Natsumi Kawasaki1
1Product Research Department Chugai Pharmaceutical Co. Ltd. Yokohama Japan.
Introduction:
Polatuzumab vedotin (Pola) is an anti-CD79b antibody-drug conjugate. Clinical evidence supports the combination efficacy of Pola with mosunetuzumab or glofitamab, both anti-CD20/CD3 bispecific antibodies (anti-CD20/CD3 BsAbs). However, the influence of Pola on the tumor microenvironment and its impact on the efficacy of anti-CD20/CD3 BsAb remains unclear.
Results:
In a syngeneic mouse model, Pola significantly increased tumor-infiltrating T cells and innate immune cells. Moreover, Pola also upregulated the levels of cytokine and chemokine involved in T-cell infiltration. The Pola + anti-CD20/CD3 BsAb combination showed superior anti-tumor efficacy versus each monotherapy.
Conclusion:
These findings suggest Pola enhances immune cell infiltration into tumors and could enhance the efficacy of anti-CD20/CD3 BsAb.
Trial Registration:
The authors have confirmed clinical trial registration is not needed for this submission.
